These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17017617)

  • 1. Endocrine therapies for sarcopenia in older men.
    Solomon A; Bouloux P
    Br J Hosp Med (Lond); 2006 Sep; 67(9):477-81. PubMed ID: 17017617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
    Hayes VY; Urban RJ; Jiang J; Marcell TJ; Helgeson K; Mauras N
    J Clin Endocrinol Metab; 2001 May; 86(5):2211-9. PubMed ID: 11344229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?
    Giannoulis MG; Martin FC; Nair KS; Umpleby AM; Sonksen P
    Endocr Rev; 2012 Jun; 33(3):314-77. PubMed ID: 22433122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hormones in the pathogenesis and management of sarcopenia.
    Kamel HK; Maas D; Duthie EH
    Drugs Aging; 2002; 19(11):865-77. PubMed ID: 12428995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IGF-I in muscular atrophy of aging.
    Borst SE; Lowenthal DT
    Endocrine; 1997 Aug; 7(1):61-3. PubMed ID: 9449034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia.
    Sun DF; Chen Y; Rabkin R
    Kidney Int; 2006 Aug; 70(3):453-9. PubMed ID: 16871256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifying muscle mass - the endocrine perspective.
    Solomon AM; Bouloux PM
    J Endocrinol; 2006 Nov; 191(2):349-60. PubMed ID: 17088404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women.
    Hofmann M; Halper B; Oesen S; Franzke B; Stuparits P; Tschan H; Bachl N; Strasser EM; Quittan M; Ploder M; Wagner KH; Wessner B
    Exp Gerontol; 2015 Apr; 64():35-45. PubMed ID: 25681638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation.
    Mak RH; Rotwein P
    Kidney Int; 2006 Aug; 70(3):410-2. PubMed ID: 16871252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss in older persons: new therapeutic approaches.
    Morley JE
    Curr Pharm Des; 2007; 13(35):3637-47. PubMed ID: 18220800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.
    Gelato M; McNurlan M; Freedland E
    Clin Ther; 2007 Nov; 29(11):2269-88. PubMed ID: 18158071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men.
    Marcell TJ; Harman SM; Urban RJ; Metz DD; Rodgers BD; Blackman MR
    Am J Physiol Endocrinol Metab; 2001 Dec; 281(6):E1159-64. PubMed ID: 11701429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged absence of myostatin reduces sarcopenia.
    Siriett V; Platt L; Salerno MS; Ling N; Kambadur R; Sharma M
    J Cell Physiol; 2006 Dec; 209(3):866-73. PubMed ID: 16972257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting myostatin for therapies against muscle-wasting disorders.
    Tsuchida K
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone, IGF-I, and the elderly. Clues to potential therapeutic interventions.
    Rosen CJ
    Endocrine; 1997 Aug; 7(1):39-40. PubMed ID: 9449029
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of anabolic hormones and insulin-like growth factor-I on muscle mass and strength in elderly persons.
    Carter WJ
    Clin Geriatr Med; 1995 Nov; 11(4):735-48. PubMed ID: 8556698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for sarcopenia and muscle weakness in older people.
    Borst SE
    Age Ageing; 2004 Nov; 33(6):548-55. PubMed ID: 15385272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myostatin polymorphisms and age-related sarcopenia in the Italian population.
    Corsi AM; Ferrucci L; Gozzini A; Tanini A; Brandi ML
    J Am Geriatr Soc; 2002 Aug; 50(8):1463. PubMed ID: 12165013
    [No Abstract]   [Full Text] [Related]  

  • 19. Muscle tissue changes with aging.
    Volpi E; Nazemi R; Fujita S
    Curr Opin Clin Nutr Metab Care; 2004 Jul; 7(4):405-10. PubMed ID: 15192443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy.
    Reardon KA; Davis J; Kapsa RM; Choong P; Byrne E
    Muscle Nerve; 2001 Jul; 24(7):893-9. PubMed ID: 11410916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.